With external innovation becoming more and more important, many firms struggle with the question of how to balance their technology-sourcing portfolio. This study addresses this issue by looking at the effects of portfolio diversity on performance outcomes and the conditions under which diversity is most likely to materialize. Using a dataset of strategic investments by pharmaceutical firms, the results show that the variance in relative technological proximity between the focal firm and its partners exhibits an inverted U-shaped relationship with innovative performance and that this relationship is affected by the diversity of the external sourcing modes used in the portfolio.

, , , ,
doi.org/10.1002/smj.2031, hdl.handle.net/1765/38043
Strategic Management Journal
Erasmus Research Institute of Management